Busch Off to Shire, Moeller Up In Bayer R&D Consolidation; Xofigo Trial Turns Up Safety Issue

 
• By Eleanor Malone

Bayer is combining its research and development organization in one unit. Discovery head Andreas Busch is leaving to join Shire while development head Joerg Moeller takes overall control. Meanwhile, Xofigo was linked to more fractures and deaths than the control arm in a prostate cancer trial.

Headquarters of Bayer’s division Pharmaceuticals in Berlin, Germany.
Bayer's pharmaceutical headquarters in Berlin, Germany • Source: Bayer AG

More from Business

More from Scrip